[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Adneuris Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100657920","phase-3-an-open-label-safety-and-efficacy-study-of-cebranopadol-in-participants-with-acute-pain-with-surgical-or-non-surgical-origin-100657920",false,"NCT07845071","An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin","An Open-Label, Single-Arm, Multiple-Dose, Phase 3 Safety and Efficacy Study of Cebranopadol in Participants With Moderate to Severe Acute Pain With Surgical or Non-Surgical Origin","Inclusion Criteria:\n\n* Adults 18 to 75 years of age.\n* Able to provide informed consent.\n* Experiencing moderate to severe acute pain related to: 1) An ambulatory surgical procedure expected to cause pain lasting at least 72 hours, or 2) A traumatic or non-traumatic musculoskeletal condition.\n* Have a pain score of at least 4 on a 0 to 10 pain rating scale before starting study treatment.\n* Willing and able to comply with study requirements\n\nExclusion Criteria:\n\n* Chronic pain condition that requires ongoing pain medication.\n* Significant medical or psychiatric condition that could affect participation or study results.\n* History of substance use disorder or misuse of alcohol or drugs.\n* Current use of medications that may interfere with the study drug or pain assessments.\n* Known allergy or intolerance to cebranopadol or permitted rescue pain medications.\n* Pregnant or breastfeeding.\n* Participation in another clinical trial or receipt of an investigational drug within the protocol-defined period before study entry.\n* Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study assessments.","ALL","18 Years","75 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.",[27],"Pain","RECRUITING","2026-10-08",{"date":31,"type":32},"2026-10-13","ACTUAL",{"date":34,"type":32},"2026-09-22",{"date":36,"type":21},"2027-02",{"name":38,"class":39},"Adneuris Therapeutics, Inc.","INDUSTRY",15,""]